The KLK7‐mediated reduction in proliferation may suggest a common mechanism shared with some other KLKs under certain conditions, which also trigger antiproliferative effects in prostate cancer (Veveris‐Lowe et al., 2005), ovarian cancer (Pepin et al., 2011; Prezas et al., 2006), and breast cancer cells (Sotiropoulou et al., 2009). This evidence concerns the gene KLK7 and breast carcinoma.